Source: Lieyun Network
Recently, iRegene, a company specializing in universal chemically induced cell therapy drugs, announced the completion of an over 100-million-yuan B-round financing. The round was co-led by Ceyuan Capital and Guosheng Capital, with participation from well-known industry investment institutions and Wuhan Optics Valley Industrial Investment. Meanwhile, the company’s B+ round financing is also nearing its final stage and is expected to close soon.
The funds from this round of financing will be used to accelerate the advancement of the company's Parkinson's disease treatment products NouvNeu001/NouvNeu003 and ophthalmic treatment product NouvSight001 in clinical trials in both China and the United States. It will also strengthen the development of multiple innovative pipelines and the establishment of clinical capabilities, as well as enhance the company’s industrialization efforts.
According to Tianyancha, iRegene focuses on the development of a new generation of chemically induced cell therapy products, aiming to provide innovative solutions for "incurable" diseases such as Parkinson's disease and blindness. As an expert in pure chemically induced cell reconstruction, iRegene's pure chemical induction system can easily reconstruct and obtain high-purity human cell types.
Dr. Jun Wei, the founder and CEO, was funded by the Rockefeller Foundation in the United States and the ORS in the UK, successively pursuing a master's degree in molecular biology and a Ph.D. in regenerative medicine in China, the US, and the UK. He has held positions such as Resident Physician at the Stem Cell Center of Union Hospital affiliated with Huazhong University of Science and Technology, Senior Research Fellow in Embryonic Stem Cells at the Roslin Institute in the UK, Expert-level R&D Leader at Axol Bioscience in the UK, and Visiting Researcher in Clinical Neuroscience at the University of Cambridge. With extensive experience in clinical treatments using stem cells, directed differentiation of pluripotent stem cells, and the construction of in vitro disease models, he has undertaken multiple projects funded by UK organizations such as the MRC and BBSCR. In late 2017, he returned to China full-time to establish Wuhan iRegene Therapeutics Co., Ltd., focusing on the development of cell-based drugs for Parkinson's disease.
As of now, the company has completed a total of 6 rounds of financing, with investors including Fortune Venture Capital, Huafang Capital, Yangtze River Innovation Investment, and GSR United Capital.